{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "licensed-product", "type": "definition", "offset": [45, 61]}, {"key": "beginning-on-the", "type": "clause", "offset": [119, 135]}, {"key": "sale-of", "type": "clause", "offset": [153, 160]}, {"key": "covered-by", "type": "definition", "offset": [183, 193]}, {"key": "a-valid-claim", "type": "clause", "offset": [194, 207]}, {"key": "licensed-patent", "type": "definition", "offset": [322, 337]}], "snippet": "means, with respect to each country in which Licensed Product is sold, on a product-by-product basis, that time period beginning on the First Commercial Sale of such Licensed Product covered by a Valid Claim in such country and expiring, on a country-by-country basis, the expiration in such country of the last-to-expire Licensed Patent with a Valid Claim.", "samples": [{"hash": "k1JJ8hh94Pp", "uri": "/contracts/k1JJ8hh94Pp#royalty-term", "label": "Exclusive License Agreement", "score": 31.3408622742, "published": true}, {"hash": "90LNHjB9dYK", "uri": "/contracts/90LNHjB9dYK#royalty-term", "label": "Exclusive License Agreement (Proteonomix, Inc.)", "score": 23.6365509033, "published": true}, {"hash": "llXY84BuOji", "uri": "/contracts/llXY84BuOji#royalty-term", "label": "Exclusive License Agreement (Synvista Therapeutics, Inc.)", "score": 21.0, "published": true}], "size": 297, "hash": "4fbc7e8942d94ccb5292d66a5d388b75", "id": 1}, {"snippet_links": [], "snippet": "has the meaning set forth in Section 8.4(b).", "samples": [{"hash": "c496cTBMO6K", "uri": "/contracts/c496cTBMO6K#royalty-term", "label": "License Agreement (Erasca, Inc.)", "score": 35.611907959, "published": true}, {"hash": "2TToQy3sh07", "uri": "/contracts/2TToQy3sh07#royalty-term", "label": "Exclusive License Agreement (BridgeBio Pharma, Inc.)", "score": 35.332649231, "published": true}, {"hash": "kgDUWhsgUYH", "uri": "/contracts/kgDUWhsgUYH#royalty-term", "label": "License Agreement (Zai Lab LTD)", "score": 33.1615333557, "published": true}], "size": 168, "hash": "8e7a156a2e658f8abeec0c4482b9c531", "id": 2}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "period-of-time", "type": "clause", "offset": [62, 76]}, {"key": "commencing-on-the", "type": "clause", "offset": [77, 94]}, {"key": "date-of-first-commercial-sale", "type": "definition", "offset": [95, 124]}, {"key": "expiration-of-the", "type": "clause", "offset": [308, 325]}, {"key": "valid-claim", "type": "clause", "offset": [341, 352]}, {"key": "roche-patent-rights", "type": "clause", "offset": [364, 383]}, {"key": "joint-patent-rights", "type": "clause", "offset": [387, 406]}, {"key": "offering-for-sale", "type": "definition", "offset": [462, 479]}, {"key": "sale-of-the-product", "type": "clause", "offset": [484, 503]}], "snippet": "means, with respect to a Product and for a given country, the period of time commencing on the date of First Commercial Sale of such Product in such country and ending on the later of the date that is (a) ten (10) years after the date of the First Commercial Sale of such Product in such country, or (b) the expiration of the last to expire Valid Claim within the Roche Patent Rights or Joint Patent Rights in such country Covering the use, manufacture, import, offering for sale, or sale of the Product.", "samples": [{"hash": "gltSt3hDb69", "uri": "/contracts/gltSt3hDb69#royalty-term", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "4JdsVkKhxkP", "uri": "/contracts/4JdsVkKhxkP#royalty-term", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "gnmJrczAfwx", "uri": "/contracts/gnmJrczAfwx#royalty-term", "label": "License Agreement (Global Blood Therapeutics, Inc.)", "score": 30.2375087738, "published": true}], "size": 127, "hash": "1a331b60368cc54d8ba729a7f62d7435", "id": 3}, {"snippet_links": [{"key": "section-642", "type": "clause", "offset": [29, 42]}], "snippet": "has the meaning set forth in Section 6.4.2.", "samples": [{"hash": "7J87KQPhGMU", "uri": "/contracts/7J87KQPhGMU#royalty-term", "label": "Research Collaboration, Option and License Agreement (Voyager Therapeutics, Inc.)", "score": 37.1834373474, "published": true}, {"hash": "c4SLfoeFyAl", "uri": "/contracts/c4SLfoeFyAl#royalty-term", "label": "Collaboration and License Agreement (Ultragenyx Pharmaceutical Inc.)", "score": 30.5824775696, "published": true}, {"hash": "czvoWYYrKuo", "uri": "/contracts/czvoWYYrKuo#royalty-term", "label": "Collaboration and License Agreement (Ultragenyx Pharmaceutical Inc.)", "score": 29.1396312714, "published": true}], "size": 124, "hash": "0d39892a7d20caf5d9bec84c305eb0d1", "id": 4}, {"snippet_links": [{"key": "section-49", "type": "clause", "offset": [36, 47]}], "snippet": "shall have the meaning set forth in Section 4.9.", "samples": [{"hash": "iveR2eaiFQT", "uri": "/contracts/iveR2eaiFQT#royalty-term", "label": "License Agreement", "score": 33.3482666016, "published": true}, {"hash": "6iabgCWcvUI", "uri": "/contracts/6iabgCWcvUI#royalty-term", "label": "License Agreement", "score": 31.8345012665, "published": true}, {"hash": "3Am0MjYyU7k", "uri": "/contracts/3Am0MjYyU7k#royalty-term", "label": "License Agreement", "score": 31.3408622742, "published": true}], "size": 91, "hash": "efa360c65f119b9a6d81028f75f7fd3b", "id": 5}, {"snippet_links": [{"key": "licensed-product", "type": "definition", "offset": [12, 28]}, {"key": "the-period", "type": "clause", "offset": [56, 66]}, {"key": "commencing-on-the", "type": "clause", "offset": [67, 84]}, {"key": "sale-of", "type": "clause", "offset": [110, 117]}, {"key": "valid-claim", "type": "clause", "offset": [213, 224]}, {"key": "licensed-patent", "type": "definition", "offset": [242, 257]}, {"key": "regulatory-exclusivity", "type": "definition", "offset": [346, 368]}], "snippet": "means, on a Licensed Product-by-Licensed Product basis, the period commencing on the date of First Commercial Sale of a Licenses Produce in a country and ending on the latest of (a) the date of the last to expire Valid Claim in a GlobeImmune Licensed Patent covering or claiming such Licenses Product in such country, (b) the date upon which all Regulatory Exclusivity for such Licenses Product expires, and (c) the tenth (10th) anniversary of the date of the First Commercial Sale of such Licenses Product in such country.", "samples": [{"hash": "gi8NqCGkHFo", "uri": "/contracts/gi8NqCGkHFo#royalty-term", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.4544830322, "published": true}, {"hash": "9Uop5UAinMB", "uri": "/contracts/9Uop5UAinMB#royalty-term", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.421628952, "published": true}, {"hash": "6Dh96ZdWGv", "uri": "/contracts/6Dh96ZdWGv#royalty-term", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.3832988739, "published": true}], "size": 69, "hash": "65f31aeb04abd0d88efff9c7f7670751", "id": 6}, {"snippet_links": [], "snippet": "has the meaning set forth in Section 4.4(b).", "samples": [{"hash": "eV2Alsg1mr7", "uri": "/contracts/eV2Alsg1mr7#royalty-term", "label": "License Agreement (Rallybio Corp)", "score": 37.2053375244, "published": true}, {"hash": "aTOfyvq2vfi", "uri": "/contracts/aTOfyvq2vfi#royalty-term", "label": "Option and License Agreement (Yumanity Therapeutics, Inc.)", "score": 33.752910614, "published": true}, {"hash": "lAdL0yvQXFJ", "uri": "/contracts/lAdL0yvQXFJ#royalty-term", "label": "License Agreement (Poseida Therapeutics, Inc.)", "score": 31.4640655518, "published": true}], "size": 63, "hash": "ddd943ed89c01f4aac01533f8e17c3ad", "id": 7}, {"snippet_links": [{"key": "section-34", "type": "clause", "offset": [29, 40]}], "snippet": "has the meaning set forth in Section 3.4 (Royalties).", "samples": [{"hash": "pxWdnQvL3", "uri": "/contracts/pxWdnQvL3#royalty-term", "label": "Exclusive License Agreement (Atara Biotherapeutics, Inc.)", "score": 25.5201911926, "published": true}, {"hash": "ftbp3NlTCGl", "uri": "/contracts/ftbp3NlTCGl#royalty-term", "label": "Exclusive License Agreement (Atara Biotherapeutics, Inc.)", "score": 25.5201911926, "published": true}, {"hash": "7WrRWlJt5zF", "uri": "/contracts/7WrRWlJt5zF#royalty-term", "label": "Exclusive License Agreement (Atara Biotherapeutics, Inc.)", "score": 25.5201911926, "published": true}], "size": 59, "hash": "534e28e5a07b6cc9abc64f9a59b68a54", "id": 8}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "beginning-on-the", "type": "clause", "offset": [58, 74]}, {"key": "sale-of", "type": "clause", "offset": [92, 99]}, {"key": "expiring-on", "type": "clause", "offset": [134, 145]}], "snippet": "means, with respect to a Product in a country, the period beginning on the First Commercial Sale of such Product in such country, and expiring on the later of:", "samples": [{"hash": "azdR3fB4KO", "uri": "/contracts/azdR3fB4KO#royalty-term", "label": "Collaborative R&d, Licensing and Option Agreement", "score": 27.0383300781, "published": true}, {"hash": "hbl3AkGQCXT", "uri": "/contracts/hbl3AkGQCXT#royalty-term", "label": "Collaboration and Option Agreement (Xencor Inc)", "score": 24.8138256073, "published": true}, {"hash": "d28fBbUKaIR", "uri": "/contracts/d28fBbUKaIR#royalty-term", "label": "Collaboration and Option Agreement (Xencor Inc)", "score": 24.7754955292, "published": true}], "size": 54, "hash": "2cd894d5f23c25adba5cf995a7cafd3e", "id": 9}, {"snippet_links": [{"key": "section-84", "type": "clause", "offset": [32, 43]}], "snippet": "shall have the meaning given in Section 8.4.", "samples": [{"hash": "hhjpuinB32m", "uri": "/contracts/hhjpuinB32m#royalty-term", "label": "Patent Assignment and Licensing Agreement (Bison Capital Acquisition Corp.)", "score": 30.2539348602, "published": true}, {"hash": "c9HIlS7micy", "uri": "/contracts/c9HIlS7micy#royalty-term", "label": "License Agreement (Bison Capital Acquisition Corp.)", "score": 30.2539348602, "published": true}, {"hash": "cKfoe2xzxvU", "uri": "/contracts/cKfoe2xzxvU#royalty-term", "label": "Patent Assignment and Licensing Agreement (Bison Capital Acquisition Corp.)", "score": 30.1143054962, "published": true}], "size": 46, "hash": "9a2a76dc10664fb0055bfa0f9d7a6d42", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIVcm95YWx0eS10ZXJtIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means, with respect to each country in which Licensed Product is sold, on a product-by-product basis, that time period beginning on the First Commercial Sale of such Licensed Product covered by a Valid Claim in such country and expiring, on a country-by-country basis, the expiration in such country of the last-to-expire Licensed Patent with a Valid Claim.", "title": "Royalty Term", "size": 3834, "id": "royalty-term", "examples": ["For purposes of determining the Royalty Rate(s) that is or are applicable on the Net Sales of Sublicensed Products during the <strong>Royalty Term</strong> pursuant to this Section 3.02 (Royalty Rates by Sublicensee and Affiliates), all Net Sales of all Licensed Products in the Territory will be aggregated on a calendar year basis."], "related": [["royalty-period", "Royalty Period", "Royalty Period"], ["license-term", "License Term", "License Term"], ["licensed-product", "Licensed Product", "Licensed Product"], ["license-period", "License Period", "License Period"], ["commercial-sale", "Commercial Sale", "Commercial Sale"]], "related_snippets": [], "updated": "2026-04-19T04:24:51+00:00"}, "json": true, "cursor": ""}}